Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View

Mitsui & Co., Ltd.

https://www.mitsui.com/jp/en/index.html

Latest From Mitsui & Co., Ltd.

India 2019 – R&D Highs, Compliance Woes And Other Lows

Bookmark
  • Analysis
By Anju Ghangurde and Vibha Ravi

2019 saw Indian companies advance innovation efforts and build and expand their specialty portfolios and biosimilars businesses. But manufacturing compliance issues weighed down several firms while on another front charges against the Singh brothers of Ranbaxy escalated.

India Regulation

Events And Losses That Shook India Pharma In The Decade

Bookmark
  • Analysis
By Anju Ghangurde

The past decade witnessed a bout of pharma 'shock and awe' events in India, some of which still reverberate across the industry. The period also marked the death of doyens of the Indian pharmaceutical sector, including the founders of Dr Reddy’s and Lupin.

India Commercial

India 2019 – R&D Highs, Compliance Woes And Other Lows

Bookmark
  • Analysis
By Anju Ghangurde and Vibha Ravi

2019 saw Indian companies advance innovation efforts and build and expand their specialty portfolios and biosimilars businesses. But manufacturing compliance issues weighed down several firms while on another front charges against the Singh brothers of Ranbaxy escalated.

India Commercial

Will FDA Inspection Observations Fog Speculated Claris Deal?

Bookmark
  • News
By Vikas Dandekar

Claris, the Indian injectables maker, has recently been served five observations by the U.S. FDA related to its manufacturing practices in India. The action coincides with chatter about a deal for the firm’s U.S. businesses which analysts believe may now face obstructions due to the regulatory uncertainty.

BioPharmaceutical India
See All

Company Information

  • Industry
  • Diversified
  • Other Names / Subsidiaries
    • Mitsui & Co. (Canada) Ltd.
    • Mitsui & Co. (U.S.A.), Inc.
    • Mitsui De Mexico, S. De R.L. De C.V.
    • Mitsui & Co. Venezuela C.A.
    • Mitsui & Co. (Chile) Ltda.
    • Mitsui & Co. (Argentina) S.A.
    • Mitsui & Co. Europe Plc
    • Mitsui & Co. Norway A. S.
    • Mitsui & Co. Deutschland Gmbh
    • Mitsui & Co. India Pvt. Ltd.
    • Mitsui & Co.(Asia Pacific) Pte. Ltd.
    • Mitsui & Co NZ Limited
    • MITSUI & CO. (AUSTRALIA) LTD.
    • MITSUI & CO. (CHINA) LTD.
    • Mitsui & Co. (Taiwan) Ltd.
    • Mitsui & Co. (Hong Kong) Ltd.
    • P T. Mitsui Indonesia
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By